← Back to Search

Radiation Therapy

SABR for Cancer

N/A
Waitlist Available
Led By Robert Olson, MD
Research Sponsored by British Columbia Cancer Agency
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
All sites of progressive disease can be safely treated based on criteria below
ECOG performance status 0-2
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at approximately the end of year 5
Awards & highlights

Study Summary

This trial is testing a new cancer treatment and measuring its toxicity. There is potential for the treatment to improve survival for people with a certain type of cancer.

Who is the study for?
This trial is for people with a limited number of cancer spread sites (up to 5), who've had their primary tumor treated, and are not candidates for surgery. They should be in relatively good health otherwise, able to consent, and complete questionnaires in English. Pregnant women or those with certain medical conditions that make radiotherapy unsafe cannot join.Check my eligibility
What is being tested?
The study tests Stereotactic Ablative Body Radiotherapy (SABR) on patients with few metastatic cancer sites. It aims to assess the side effects and potential survival benefits of this targeted high-dose radiation therapy compared to other treatments.See study design
What are the potential side effects?
Potential side effects include skin reactions at the treatment site, fatigue, nausea, pain or swelling around the treated area. There may also be risks specific to where the SABR is directed; for example, lung inflammation if treating chest metastases.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
All my cancer growths can be safely treated.
Select...
I can take care of myself and am up and about more than half of the day.
Select...
My brain metastases have been approved for treatment by a specialized team.
Select...
I am not a candidate for surgery to remove my cancer as advised by my medical team.
Select...
My cancer has spread, and this was confirmed by tests.
Select...
I can take care of myself and am up and about more than half of the day.
Select...
My cancer fully responded to the last treatment, as shown by scans.
Select...
I have had treatment for my cancer that has spread.
Select...
I had a non-radiation treatment for my cancer and might have residual disease.
Select...
I had standard radiation therapy and may be eligible for SABR if deemed safe.
Select...
I have had an MRI of the spine due to cancer spread to my spine or nearby.
Select...
My non-brain cancer spot is no larger than 3cm if treated with a single radiation dose.
Select...
My tumor is between 3.1 and 4cm, and I can consider a specific radiation dose.
Select...
My brain metastases have been approved for treatment by a specialized team.
Select...
My cancer outside the brain is 6 cm or smaller, except for safe-to-treat large bone metastases.
Select...
My primary cancer was treated with intent to cure or controlled with prior therapy.
Select...
My primary cancer was treated with intent to cure or controlled with prior therapy.
Select...
I am not a candidate for surgery to remove my cancer.
Select...
My non-brain cancer spot is no larger than 3cm if treated with a single radiation dose.
Select...
I have not necessarily had a biopsy of my metastasis.
Select...
I will not receive certain cancer drugs 2 weeks before to 1 week after my radiation treatment.
Select...
My cancer has spread, and this was confirmed by tests.
Select...
I have up to 5 cancer spots that can be treated with targeted radiation.
Select...
I've had a CT scan of my chest, abdomen, and pelvis, or a PET-CT as required.
Select...
I only need a PET-CT or PSMA-PET scan for certain conditions, not the full set of scans.
Select...
I have not been treated with SABR for my current cancer sites.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at approximately the end of year 5
This trial's timeline: 3 weeks for screening, Varies for treatment, and at approximately the end of year 5 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Patient-reported Quality of life, function and health status using BC Cancer's Prospective Outcomes and Support Initiative (POSI).
Toxicity as Assessed by the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 4 for each organ treated (e.g. liver, lung, bone)]
Secondary outcome measures
Lesional control rate, defined as lack of further progression
Overall survival
Progression-free survival

Trial Design

1Treatment groups
Experimental Treatment
Group I: Stereotactic armExperimental Treatment1 Intervention
Stereotactic ablative radiotherapy

Find a Location

Who is running the clinical trial?

British Columbia Cancer AgencyLead Sponsor
171 Previous Clinical Trials
90,112 Total Patients Enrolled
Robert Olson, MDPrincipal InvestigatorBC Cancer Agency - Centre for the North
1 Previous Clinical Trials
204 Total Patients Enrolled

Media Library

Stereotactic Ablative Body Radiotherapy (SABR) (Radiation Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT02933242 — N/A
Cancer Research Study Groups: Stereotactic arm
Cancer Clinical Trial 2023: Stereotactic Ablative Body Radiotherapy (SABR) Highlights & Side Effects. Trial Name: NCT02933242 — N/A
Stereotactic Ablative Body Radiotherapy (SABR) (Radiation Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02933242 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research project continue to accept participants?

"It is evident from the data present on clinicaltrials.gov that this trial, which was initially posted in November 2016 and last updated in October 2022, has suspended its recruitment of patients. Nevertheless, there are 636 other trials being conducted at the moment that welcome new participants."

Answered by AI
Recent research and studies
~58 spots leftby Jul 2025